Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer

Inclusion Criteria: * Metastatic or unresectable cancer and considered by their physician to be indicated for a new line of SOC as listed in the protocol * Are ineligible for a disease specific clinical study with IMM-101 * Have an estimated life expectancy greater than 3 months (from Day 0) * Give signed informed consent for participation in the study * Have an Eastern Cooperative Oncology Group (ECOG)/World Health Organisation (WHO) Performance Status of ≤2 at Day 0. * Have adequate bone marrow, hepatic and renal function Exclusion Criteria: * Patient has previously received treatment with IMM-101 * Patient is currently part way through a course of chemotherapy or immunotherapy * Patient is receiving concomitant treatment with another investigational product * Patient has received an investigational drug within the 4 weeks prior to IMM 101 administration * Patient has significant cardiovascular disease * Patient has any previous or concurrent malignancy (excluding adequately treated carcinoma in situ of the cervix, basal cell carcinoma of the skin and/or non melanoma skin cancer, or if previous malignancy was more than 5 years prior to Screening and there are no signs of recurrence) * Patient has co existing active infection or medical condition which will substantially increase the risk associated with the patient's participation in the study * Patient has uncontrolled hypercalcaemia * Patient has previously experienced an allergic reaction to any mycobacterial product. * The patient has a history of non-infectious pneumonitis that required steroids or current pneumonitis * Patient has received live vaccine within 30 days of planned start of study medication * Patient is pregnant or a breast feeding woman. * Patient is unwilling to use a medically acceptable, effective method of contraception throughout the treatment period and for at least 6 months after discontinuation of treatment. * Patient has used depot corticosteroids in the 6 weeks before initiation of Screening * Patient has had chronic use of systemic corticosteroids within the 2 week period before the first administration of IMM-101 * Patient has received a blood transfusion within 4 weeks prior to Screening * In the opinion of the Investigator, the patient is unable or unwilling to comply with the protocol.